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Background: The new coronavirus called COVID-19 originated in the city of Wuhan, China and has currently 
spread to different continents, leading the World Health Organization (WHO) to declare a “pandemic”. Therefore, 
the aim of this review was to present a new proposal for a care protocol in Peruvian Dentistry: Provisional review 
of the diagnosis, treatment, epidemiological characteristics, routes of transmission and recommendations of CO-
VID-19. 
Material and Methods: A search of digital scientific literature was made in the databases: Science Direct, Pubmed 
and Google Scholar. The Boolean operators AND, OR and NOT: “Covid-19” “Dental” “Routes of transmission. 
They were included Scientific articles published in English between December 2019 - March 2020. 
Results: Different studies were found mainly of epidemiological, observational and experimental design. On March 
6, 2020, the President of the Republic of Peru confirmed and declared in Peru the beginning of the first case of 
coronavirus. According to reports from the Ministry of Health (MINSA) as of July 30, there are: PCR (+) 108, 299; 
Rapid test (+) 292, 384 positive cases and 18, 816 deceased with a lethality of 4.7%. 
Conclusions: Within the limitations of this literature review, the presence of the virus is inevitable in dental practi-
ce. The dentist must understand the evolution of this microorganism like all vulnerable professionals in the health 
sciences.
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Introduction
On December 12, 2019, the authorities of the cities of Wu-
han, China reported that there were 27 cases of an atypical 
viral pneumonia. What most of the affected people had 
in common was that they had been exposed to wild ani-
mals at the market in which it was usual to commercialize 
exotic birds, snakes, bats and other types of wild animals. 
The disease was identified from the samples of the affec-
ted patients evaluated as being caused by a novel type of 
coronavirus, which was temporarily named COVID-19 
by the World Health Organization (WHO) and is now 
considered a pandemic that is rapidly infecting the entire 
planet (1). Initially the symptoms were diffuse, but as the 
casuistry of infected people increased, the following clini-
cal symptoms were found to be typical among the patients 
suffering from this “new” viral disease: cough, headache, 
fever and in some cases hemoptysis and diarrhea (2-4). 
This new COVID-19 coronavirus identified in humans 
has managed to mutate to be transmitted among subjects 
of the same species. It has been reported that saliva is 
one of the large viral reserves, making transmission very 
easy and fast by contact with the droplets that are expe-
lled when coughing, talking, kissing, etc. Dentistry is a 
branch of medicine that is at high risk, since the grea-
test clinical activity occurs in the oral cavity with close 
contact with saliva, crevicular fluid, and blood, among 
other fluids. Indeed, the infectious potential of saliva is 
so high that current diagnostic methods for this new co-
ronavirus are made by obtaining a fluid sample from the 
oral mucosa and oropharynx, allowing rapid, non-inva-
sive detection of early infection by COVID-19 (5).
In a message to the nation made at 8:57 a.m on March 
6, 2020, the President of the Republic of Peru confirmed 
the “First Case Zero “ in the city of Lima. The so-called 
“Case Zero” was a 25-year-old male patient with a his-
tory of having been in Spain, France and the Czech Re-
public several weeks previously. As of March 11, 2020, 
more than 100 days after the initiation of the epidemic, 
86 cases have been confirmed in Peru, most being close 
relatives of “Case Zero”. According to the Ministry of 
Health of Peru (MINSA), early diagnosis is recommen-
ded with isolation of the infected patient, constant hand 
hygiene and avoidance of contact with infected people, 
among other guidelines (6,7).
As a consequence of the limited scientific evidence 
regarding COVID-19 infection and because the den-
tal community is a group at high risk of contagion and 
dissemination of this infection, the Faculty of Dentis-
try of the Universidad Nacional Mayor de San Marcos 
(UNMSM) has expressed its commitment to Peruvian 
Dentistry. Therefore, for this reason the objective of this 
bibliographic research is to present a provisional review 
of the diagnosis, treatment, epidemiological characteris-
tics, routes of transmission and recommendations of the 
new coronavirus (COVID-19) in Peruvian dentistry.
Material and Methods
A search of electronic scientific literature was made 
in the databases: Science Direct, Pubmed and Google 
Scholar. The Boolean operators AND, OR and NOT: 
covid-19* OR dental*. They were included Scientific 
articles published in English between December 2019 
- March 2020. Data extraction was made according the 
following PICO elements strategy:
P (Problem): Covid-19 viral infection
I (Intervention): Use of dental care protocol
C (Comparison): Other care protocols
O (Outcome of Interest): Maintain a minimum risk of 
infection in dental care
- Inclusion and exclusion criteria
Descriptive, epidemiological, experimental design stu-
dies on Covid-19 in dentistry.
Studies describing protocol of dental care
Studies describing transmission routes in dental care
Studies that are not published between December 2019 
and March 2020
Studies in a language other than English
-Data extraction
The search was carried out individually by the study au-
thors through manual consultation. The data was extrac-
ted in relation to the subject of evaluation, year of pu-
blication, methodology. A meta-analysis was not carried 
out because the study only presents a literature review.
-Risk of bias
Being a literature review, it is initially considered a po-
tential risk of bias, which is stated in the conclusions of 
this study.
Results
-Origin and characteristics of the covid-19
The new coronavirus is a microorganism belonging to the 
β genus. This virus, which is currently known as 2019-
nCoV, has an approximate diameter of 60 nm to 140 nm 
and is polymorphically encapsulated with oval particles. 
In addition, this virus has certain genetic characteristics 
that are inconsistent with SARSr-CoV (SARS-related 
coronaviruses) and MERSr-CoV (MERS-related coro-
naviruses). However, some recent research has shown 
that it has more than 85% homology to SARSr-CoV, and 
it seems to attach to the epithelial cells of the respiratory 
system (Fig. 1) (7-9).
The Coronaviridae family includes coronaviruses of the 
order Nidovirales, which have a single chain, RNA ge-
nome. Currently, there are four genera of coronaviruses: 
α-CoV, β-CoV, γ-CoV, and δ-CoV, and most of these co-
ronaviruses mainly infect humans and some minor ver-
tebrates (10-13).
These pathogens have a high impact on human and ani-
mal health since they generally cause respiratory and 
digestive diseases, and can be fatal in certain clinical 
situations. To date, the reported mortality rate in the city 
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	Fig. 1: Genomic characteristics of the COVID-19.
of Wuhan (China) is of around 3.8%. This city was the 
epicenter of today’s pandemic after the deveopment of 
an outbreak of an atypical picture of feverish respiratory 
disease due to the new COVID-19. The genetic sequen-
ce of this virus was made available to the WHO on 12 
January 2020 allowing multiple laboratories in different 
countries to develop a specific polymerease chain reac-
tion (PCR) diagnostic test to detect the new infection. 
According to the WHO, 2019-nCoV has at least 70% 
similarity with SARS-CoV, which is why it has been na-
med COVID-19 (14).
According to the study by Lauer et al. the average incu-
bation period for COVID-19 is approximately 5 days, 
similar to SARS. Assuming that infection occurs at the 
start of monitoring, it has been estimated that 101 out of 
10 000 cases will develop symptoms after 14 days of ac-
tive monitoring or quarantine.  These are very important 
data for public health officials to establish evidence-ba-
sed public prevention and control policies (15).
The genesis and virulence of COVID-19 remains uncer-
tain. Most of the zero patients were linked to the Wuhan 
market in China, although, 13 of the 41 infected patients 
had no link to that location. Indeed, the so-called “ Pa-
tient Zero “ became ill on December 1, 2019 and had no 
link to the market in question, and moreover, there was 
no evidence of an epidemiological link between the first 
patient and the other infected subjects, thereby sugges-
ting that the wild animal market was not the only place 
from which the virus had spread. The hypothesis that the 
virus infiltrated the market and spread from there was 
likely fabricated, however, blood tests performed in peo-
ple and animals in the market could shed more light on 
the origin of the COVID-19 (2,16,17).
For example, because coronaviruses are microorganisms 
that can affect animals and humans, they are considered 
the predominant cause of the common cold (1,2). Howe-
ver, two coronaviruses are known to have greater clini-
cal impact, and these are associated with more serious 
diseases: the SARS coronavirus (2002–2003) and the 
respiratory syndrome of the Middle East (2012) (18,19). 
The new COVID-19, which belongs to the B β -COV 
lineage, with a single-stranded positive-sense RNA en-
capsulated by an envelope has now been added to that 
list (20,21).
-Epidemiology
Epidemiologically, the new COVID-19 is a highly in-
fectious virus, which, according to the literature, can 
survive approximately 2 hours in the environment and 
has an incubation period of approximately 4 to 8 days 
after infection. This virus does not distinguish between 
age groups, race, sex, or any other condition. However, 
elderly patients with several comorbidities are genera-
lly more prone to present a severe course of the disea-
se. It is important to note that young people without a 
systematic history seem to remain asymptomatic. Up to 
now, respiratory drops have been considered the main 
route of transmission, although the fecal-oral route may 
be another source of entry for COVID-19 since nucleic 
acids from the virus can be present in stool samples from 
infected patients (22-24).
On the other hand, another source of contamination is 
vertical transmission between a mother and her infant. 
According to some studies carried out at the Wuham 
Children’s Hospital newborns of up to 30 hours have 
shown to be infected with COVID-19. In addition, some 
studies suggest that the ocular route should not be ig-
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nored because the lining of the eye socket can quickly 
become infected with droplets and other body fluids (25-
27).
Zhu et al. (28). reported that COVID-19 has been iden-
tified as being phylogenetically closer to certain β-coro-
naviruses detected in some bats belonging to the Sarbe-
covirus subgenus of the coronaviridae family, and that 
this virus is 75-80% identical to SARS-CoV and 40% to 
MERSCoV. Therefore, it has been proposed that 2019-
nCoV may share the same infection routes as SARS-
CoV and MERS-CoV. In addition, some studies have 
shown that COVID-19 can develop more effectively in 
the epithelial cells of the airways, indicating that that 
COVID-19 employs a cell receptor human angiotensin 
converting enzyme 2 (hACE2) similar to that of SARS-
CoV. (21,28).
The first case in Latin America was presented by a 
61-year-old Brazilian man who had traveled to Italy 
in February 2020, where a significant outbreak of this 
virus is currently ongoing. The man was symptomatic 
on arrival home and was referred to the Albert Einstein 
Hospital in São Paulo, Brazil, with an RT-PCR test being 
positive for coronavirus. This was the first case repor-
ted in a South American country with a large popula-
tion of inhabitants that has experienced previous signifi-
cant outbreaks of infections declared to be world health 
emergencies by the WHO (Fig. 2) (29).
The first case of coronavirus in Peru was confirmed on 
Friday March 6, 2020. The Ministry of Health (MINSA) 
called for Peruvians to remain calm and confirmed that 
the state was prepared to face this pandemic (Table 1). 
It was declared that patients diagnosed with cornavirus 
should be transferred to 5 hospitals in the city of Lima 
in order to provide optimal treatment and care: Villa el 
Salvador Emergency Hospital, Hipólito Unanue Hospi-
tal in Agustino, Dos de Nacional Hospital May in the 
Cercado, Hospital de Vitarte in Ate Vitarte and Hospital 
Sergio Bernales de Collique (7).
Although it is known that severe cases of COVID-19 are 
few compared to the total number of infected worldwi-
de, the MINSA indicated that diagnosed cases will be 
monitored at home, and the Peruvian State will cover 
all the costs of treating the coronavirus according to the 
Ministerial Resolution N ° 039-2020-MINSA. Similarly, 
the National Institute of Health was designated as the 
only National Reference Laboratory authorized to diag-
nose COVID-19 through the corresponding biological 
analysis (Table 1) (7).
-Spread of covid-19 in Latin America
Within this critical situation scenario, Latin American 
countries have been the last to report cases of patients 
infected with coronavirus. On March 12, 2020, the 
WHO declared new COVID-19 a “pandemic” since it 
now affects all the continents of the world.  Since the 
beginning of the millenium, three pathogenic outbreaks 
have been declared: SARS-CoV in 2002, the MERS-
CoV virus in 2012 and now, the outbreak of the new 
COVID-19.  This last microorganism develops rapidly 
and infectiously making it a pandemic in the world. Al-
though the overall mortality rate is lower than that other 
viruses, mortality in elderly patients with systemic di-
seases ranges between 17-38% (18,19). To date, there is 
no specific treatment, and only one therapy for symptom 
management has been recommended (27,30-33).
Latin America is characterized by diverse climates of 
temperature, relative humidity and wind speed, which 
can be considered risk factors that must also be addres-
sed because they can exacerbate COVID-19 transmis-
sion. Moreover, cold seasons can condition certain viru-
ses such as SARS and influenza (34). It has been shown 
	
Fig. 2: Wuhan Coronavirus COVID-19 in Peru and other global cases (07/30/2020). Provided by JHUCSSE.
J Clin Exp Dent. 2020;12(10):e979-90.                                                                                                                                                                                             COX-1 and -2 in oral surgical model
e983
Country Region PCR (+) Quick Test (+) Total Cases(+) Deaths Lethality (%)
Lima metropolitana 68025 126154 194179 8061 4.1%
Callao 5554 15344 20898 1020 4.8%
La libertad 2588 12134 14722 1327 9.0%
Arequipa 3232 9974 13206 718 5.4%
Moquegua 158 2594 2752 80 2.9%
Cusco 1628 2406 4034 80 1.9%
Lambayeque 2064 14890 16954 1215 7.1%
Piura 937 19865 20802 1251 6.0%
Amazonas 815 4483 5298 123 2.3%
Ica 2436 9105 11541 804 6.9%
Junin 1447 5829 7276 402 5.5%
Ancash 2410 9260 11670 818 7.0%
Peru Cajamarca 1891 3669 5560 201 3.6%
Huanuco 942 5027 5969 191 3.2%
Apurimac 78 780 858 37 4.3%
Puno 231 1808 2039 72 3.5%
Tacna 628 1988 2616 30 1.1%
Loreto 3069 8012 11081 545 4.9%
San martin 1940 6318 8258 319 3.8%
Ayacucho 1309 2302 3611 74 2.0%
Huancavelica 237 1314 1551 37 2.3%
Pasco 143 1683 1826 43 2.3%
Tumbes 529 3561 4090 209 5.1%
Ucayali 933 8804 9737 231 2.3%
Madre de dios 818 2352 3170 97 3.0%
Lima región 4257 12728 16985 831 4.8%
Table 1: Peruvian departments affected with cases of COVID-19.
that the first Latin American countries presenting infec-
tion were Brazil and Mexico, leading to the question as 
to whether   Latin American health systems are ready for 
this. Similar to other countries in the world, Latin Ame-
rican countries are still under development, and therefo-
re, it is assumed that a pandemic of this nature can consi-
derably affect public health (19). It is therefore essential 
to intensify communication efforts. In South America, 
there is great diversity in economic, social, and politi-
cal development, among other areas. For example, some 
countries such as Haiti have a low development index, 
similar to Venezuela, which is going through a very se-
rious social, cultural and economic crisis. Taking this 
into account, the impact of the new COVID-19 pande-
mic could be more catastrophic in these countries com-
pared to others with more evolved economies (Table 2) 
(Fig. 3) (35,36).
- Myths and truths
Various myths have been debunked by MINSA and the 
WHO in order to placate Peruvians since a lack of infor-
mation to the population may exacerbate the number of 
newly infected patients (Table 3) (7,14).
-Signs and symptoms
Patients infected with COVID-19 present with charac-
teristic symptoms such as fever, dyspnea, dry cough, 
headache, nasal congestion, and other symptoms of 
the upper respiratory tract. However, although atypical 
symptoms may be present, fever remains the most typi-
cal symptom of COVID-19 infection (2,28). According 
to a current epidemiological survey, the symptoms of 
COVID-19 infection are not specific and can be confu-
sed with other pathologies because the most common 
symptoms are the appearance of fever, and general 
weakness, with some people reporting myalgia and hea-
Source: Coronavirus COVID-19 Global cases by Ministry of Health of Peru. Last update: 07/30/2020 13:52:03 p.m.
PCR: Protein Chain Reaction test
(+): Positive cases














Table 2: Confirmed cases in Latin America with COVID-19.
Source: Coronavirus COVID-19 Global cases by Johns Hop-
kins CSSE mobile version.










Fig. 3: Scheme of Latin American countries affected by COVID-19. 
Source: Coronavirus COVID-19 Global cases by Johns Hopkins CSSE mobile version
Last update: 07/30/2020 14:00:00 p.m.
dache among other symptoms. Diarrhea has been des-
cribed in 10.6% and up to 30% of patients with SARS 
and MERS, respectively (21).
On the other hand, some patients present difficulty in 
breathing and may develop more acute clinical pictu-
res, coagulation disorders and septic shock, while it is 
of note that some patients may be afebrile or asympto-
matic (17,37,38). In addition, at the onset of the disea-
se, infected children can present fever, dry cough, na-
sal congestion and headache, among other symptoms. 
However, most children generally improve after 1 week 
of evolution. Nevertheless, while the condition of some 
children can progress and evolve rapidly without major 
complications, the disease should be closely monitored 
for 1 to 3 days (17,37,38).
In relation to COVID-19 infection during pregnancy, 
maternal hypoxemia caused by a severe viral infection 
can lead to birth defects. Newborns, especially prema-
ture babies, are more likely to have insidious and nons-
pecific symptoms. However, most have a favorable evo-
lution and usually recover within 1 to 2 weeks, with no 
deaths having been reported in this age group (6). The-
refore, some criteria have been established to determi-
ne whether a possible case is infected with COVID-19 
(Table 4) (8).
-Diagnosis
The following guidelines are recommended (8):
• Clinical-physical examination: The vital functions of 
potentially infected patients should be monitored with 
special focus on respiratory sounds, and the presence of 
dyspnea, rhinorrhea, fever, etc.
• Imaging test: An imaging test should be performed, es-
pecially in patients with severe infection. The findings 
may vary with age, immunity, and stage of the disease, 
which must be differentiated from other viral diseases.
• Microbiological analysis: Nasopharyngeal swabs or 
sputum samples should be obtained for microbiological 
analysis. In addition, PCR assays for COVID-19 should 
be performed. However, the first case of COVID-19 
in the United States was found to be negative in blood 
serum likely due to the deficient testing methods first 
used (17,24,39).
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Myths Truths
It is spread by receiving packages from abroad. The COVID-19 does not survive long on inert surfaces.
The new COVID-19 is transmitted by insects. The COVID-19 is not transmitted by insects.
Cold weather kills COVID-19. Cold temperatures do not kill the COVID-19.
Drinking urine protects against the COVID-19. Children’s urine does not protect against the COVID-19.
Coins, bills and credit cards COVID-19. The risk is low because the COVID-19 only lives a few hours.
Pets can be infected by COVID-19. There is no evidence that the new COVID-19 infects pets.
The new COVID-19 can fly up to 8 meters away. There is only evidence that they reach up to 1 meter.
Does wearing a mask prevent me from getting it? Masks should only be used by people already infected and 
health care personnel.
Passengers arriving from abroad are potentially infected. Only if they have been in risk areas for the past few weeks.
Contact with feces of an infected person can spread 
COVID-19.
There is a low risk, hand washing before and after using the 
toilet is recommended.
Table 3: Confirmed cases in Latin America with COVID-19.
Source: Peruvian Ministry of Health (7).
Number Definition of suspected infected 
patient
1 Fatigue
2 Has a fever> 38 ° C
3 Diarrhea
4 Dyspnoea
5 With or without dry cough
6 Muscle and / or joint pain
Table 4: Criteria for considering a possible infected 
case.
-Treatment (management)
• Home management: The patient should be isolated and 
resting at home with monitoring of vital signs (pulse, 
blood pressure, heart rate, respiratory rate etc.), and with 
adequate hydration and alimentation. In more severe 
cases, specialized surveillance is needed, with monito-
ring of organ functions (liver enzymes, urea nitrogen, 
myocardial enzymes, bilirubin creatinine, urine volume, 
etc.) (8).
• Antiviral treatment: There is currently no evidence 
from clinical trials that retrovirals serve as specific treat-
ment for coronavirus in suspected or confirmed cases 
(8).
• Corticosteroid therapy: Glucocorticoid administration 
should be made with caution. For example, methylpred-
nisolone may be indicated in a patient with an acute 
course of the disease, although the recommendation is 
weak (8). Nonetheless, the most important thing, is to 
isolate, track, and quarantine possible infected patients] 
(17,38,39).
Discussion
Several studies are currently ongoing in an attempt to eli-
minate the virus. Xuentin et al. (40) found that hydroxy-
chloroquine is more potent in vitro than chloroquine to 
inhibit SARS-CoV-2. Although, there is no specific re-
commended antiviral treatment for coronavirus, and no 
vaccine is currently available, treatment is symptomatic 
and oxygen therapy represents the main therapeutic in-
tervention for patients with severe infection. Mechanical 
ventilation may be necessary in cases of respiratory fai-
lure refractory to oxygen therapy, while hemodynamic 
support is essential to control septic shock (27).
On the other hand, in some countries it has been sug-
gested that the anti-HIV drug, nelfinavir, may be active 
against COVID-19 and could be a potentially effective 
drug. In addition to the previously described therapy, 
Chinese doctors have begun conducting clinical trials 
using stem cells and traditional Chinese medicine for 
severely ill patients. The results of these treatments will 
hopefully improve the evolution of patients infected 
with coronavirus (27-41).
As preventive treatment, the Ministry of Health (MIN-
SA) of Peru recommends to (7):
Wash your hands frequently with soap and water (for 
a minimum of 20 seconds). Avoid touching your nose, 
mouth, and eyes. When sneezing or coughing, cover 
your nose and mouth with your forearm or disposable 
tissue. Avoid direct contact with people with respiratory 
problems. It should be noted that according to world ca-
suistry, around 80% of confirmed cases infected with co-
ronavirus recover without complications. Nevertheless, 
approximately 1 in 6 people can develop severe infec-
tion with difficulties in breathing, and according to the 
WHO, 2% of people with respiratory diseases, diabetes, 
heart disease or a depressed immune system can die (7).
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-Dental transmission routes
Since it has been shown that the COVID-19 can be 
spread from person to person through the micro-drops 
that are expelled from the airways and with knowled-
ge of the incubation period, it has been confirmed that 
this virus infects the cells through the same routes as 
other viruses such as SARS (11). The risk of infection of 
COVID-19 is highly dangerous due to the ease of conta-
gion through verbal communication, body fluids, saliva, 
non-sterile instruments, etc. As dentistry is a field which 
involves direct contact with the oral cavity, viruses can 
be easily transmitted in the dental environment through 
aerosols that are suspended in the air of the dental office, 
and these can enter the guest through oral, ocular and 
nasal mucosa (Fig. 4) (42).
	
Fig. 4: COVID-19 transmission routes in the dental office.
•Aerosol contamination of the handpiece: Most dental 
units produce aerosols and drops that are highly virus-la-
den when caring for a carrier patient. The transmission 
of these drops with COVID-19 is the greatest concern 
in hospitals, since it is practically impossible to avoid. 
These droplets of saliva combined with traces of blood 
become a time bomb for the spread of this disease. The-
se drops can remain in the environment and enter the 
airways of the respiratory tract, making the COVID-19 
virus highly contagious and able to spread rapidly in 
dental practice.
•Constant contact with saliva: Frequent direct or indi-
rect contact by a dental professional with contaminated 
human saliva, blood, dental instruments, impression 
materials, and dental instruments or dental office sur-
faces make this a direct route for the spread of the co-
ronavirus. In addition, dental operators, assistants, and 
office patients can quickly become infected through the 
mucosa. Therefore, clinical care protocols are needed in 
order to avoid infection with COVID-19 through these 
contamination routes (4,43-49).
• Direct contact with infected people: Human coronavi-
ruses such as SARS-CoV and MERS-CoV can persist 
on surfaces such as glass, metal, plastic for up to two 
days. Therefore, contaminated surfaces and dental ins-
truments such as rubber cups, dam holder, trays etc. are 
a source of contamination. On the whole, dental treat-
ments involve contact with saliva and this bodily fluid 
can contaminate the surfaces of a dental office even if 
patients are inactive. Moreover, it has been demonstra-
ted that these viruses can survive hours in the environ-
ment. Thus, it is recommended to maintain the work un-
der constant disinfection to reduce the risk of becoming 
infected by COVID-19. Furthermore, it is recommended 
to avoid contact with contaminated surfaces and instru-
ments when proper sterilization has not been carried out 
in order to avoid possible cross infection among patients 
(4,48-49).
-Management protocol in dentistry
In its capacity as the oldest and most prestigious faculty 
in Peru and Latin America, the Faculty of Dentistry of 
the Universidad Nacional Mayor de San Marcos foun-
ded on May 12, 1551 proposes the present protocol of 
perfectible and primary management to avoid contagion 
and propagation of cases of coronavirus in Peruvian 
dentistry.
Dental professionals should be familiar with the develo-
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pment, spread and evolution of COVID-19 and should 
be able to identify patients with coronavirus infection 
and take the necessary extra protective measures that 
should be taken during clinical practice. To avoid CO-
VID-19 transmission  dental professionals are recom-
mended to carry out the following infection control 
measures, taking into account that sprays and drops are 
considered the main propagation routes of COVID-19 
(4,7,8,50-55).
Guidelines for the use of common protective medical 
products in the prevention and control of coronavirus in 
dental practice (7,8,14,17).
1. First: Do not accept patients with obvious signs and 
symptoms (Table 4) of COVID-19 but rather refer them 
to the respective health authorities for the proper mana-
gement of active disease and avoid unnecessary spread.
2. Second: Evaluate the patient using a brief question-
naire to facilitate rapid decision making by the dentist. It 
is recommended to ask questions regarding possible risk 
factors: (a) Have you had a fever in the last two wee-
ks? (b) Have you had respiratory problems, shortness 
of breath, cough, in the last two weeks? Before dental 
treatment, patients should be triaged to quickly identify 
those suspected of coronavirus. The following scenarios 
can be found:
In the case of fever > 38ºC,  treatment must be postponed 
and the patient must be immediately referred to MINSA 
for evaluation to rule out coronavirus.
In the absence of fever (<37 ºC) patients should be trea-
ted with the biosecurity measures described below.
3.Third: The waiting room must be adequately ventila-
ted. The time between receiving different patients should 
not exceed 30 minutes and crowding in the waiting room 
must be avoided. Office furniture and surroundings must 
be disinfected.
Magazines, books, brochures or any other printed mate-
rial should not be made available  to avoid possible cross 
contamination between patients.
4. Fourth: Hands of both the patient and dental operators 
and assistants should be washed with soap and water for 
at least 20 seconds and dried with a disposable paper 
towel before and after the care of each patient. It is also 
recommended to use gel based on hydroalcoholic solu-
tion at 70% on the palms of the hands for 20 seconds, 
rubbing well between the fingers until dry.
5. Fifth: The dentist and healthcare personnel must use 
barrier biosecurity protection methods that include:
• Mask: a new one mask should be used for each patient 
since the service life  is short (1 to 2 hours) and potentia-
lly dangerous microorganisms can remain.
• Latex surgical gloves: It is recommended to use gloves 
for each type of treatment. For example, after the deter-
mination of the absence of potential signs and symptoms 
of infection during triage, a new pair of disposable glo-
ves should be used for the treatment of the patient. Re-
member that glove changing is not a substitute for hand 
hygiene.
• Mouthwash: The use of a 0.12% chlorhexidine-based 
mouthwash for 60 seconds before each dental procedure 
will reduce microbial load.
• Protective glasses: They must be used at all times to 
protect the eye cavities, and thus, avoid any type of con-
tamination. The glasses should be used before, during 
and after treatment. Disinfect with sodium hypochlorite 
or alcohol before reuse with another patient.
• Protective mask: It is recommended to use protective 
masks since dental procedures commonly involve con-
tact with blood, saliva or other oral fluids. Special care 
should be taken when using rotating elements.
• Disposable Apron gown: It is recommended to use dis-
posable gowns to avoid contact with saliva, blood and 
other fluids, which may splash onto the operator’s clo-
thing, to thereby avoid the transfer of microorganisms 
home, at work or other establishments. It is strictly for-
bidden to go outside in clinical care workclothes. Gowns 
must be changed and disposed of after each patient/treat-
ment.
• Rubber dam: It is mandatory to use this accessory, es-
pecially in the initial stages of the coronavirus pande-
mic, since it isolates the tooth to be treated from germs, 
saliva, blood and other fluids, thus reducing microbial 
load.
• Handpiece: A rotary instrument with an anti-retraction 
valve should be used since the possibility of contamina-
ting the aerosol with viruses and other microorganisms 
is increased, and it has been shown that the anti-retrac-
tion system can significantly reduce the return flow of 
oral microorganisms.
• Disinfection and sterilization: It is mandatory to carry 
out the antisepsis of all personal property, stools, dental 
chair, among other elements, using sodium hypochlori-
te, hydrogen peroxide, 70% alcohol and/or other disin-
fectants with scientifically proven antimicrobial activity.
• Biomedical Waste Management: Eliminate waste res-
pecting the classification colors proposed by MINSA. 
Sharp elements must be classified and properly sepa-
rated from the other waste products. It is mandatory to 
have an official biomedical waste collection system with 
a company duly registered and authorized by MINSA.
Taking into account all of the above and in accordance 
with Ministerial Resolution No. 084-2020-MINSA, the 
Faculty of Dentistry of the UNMSM proposes the fo-
llowing flowchart for care of patients with coronavirus 
(Fig. 5) (7,8,14,17).
Conclusions 
In conclusion, within the limitations of this literature re-
view the presence of the word virus in the expression of 
the dental professional is not new. Dentists are prepared 
to act quickly in the presence of bacteria, fungi, parasites 
J Clin Exp Dent. 2020;12(10):e979-90.                                                                                                                                                                                             COX-1 and -2 in oral surgical model
e988
	Fig. 5: Flow chart of the new proposal of patient COVID-19 care in the dental office by the Faculty of Dentistry of the UNMSM.
and prions. The problem is to placate the population that 
goes to a dental service, and in this respect two paths 
can be taken, that of confusion or the path of knowled-
ge. Occasionally, a virus is driven by the biological ele-
ment best studied in dentistry, that is saliva, although the 
biochemical properties of Wharton’s secretion from the 
Rivinus ducts help in digestive processes On the other 
hand, today saliva is the vehicle leading to the shortage 
of masks that protect against particles of the coronavirus 
throughout the world.
Dental office biosecurity measures begin by questioning 
patients whether they have or have had fever or respi-
ratory problems. Dental equipment is internally disin-
fected through the air system and water lines involving 
mainly the high-pressure hand piece are disinfected with 
sodium hypochlorite. Disinfection of all the surfaces of 
a dental unit is vital.
The second step is to place barriers between the patient 
and the operator, with special protection of the oral, na-
sal and ocular mucosa, being routes through which the 
coronavirus can be transmitted. This protection inclu-
des the use of protective glasses, masks, caps, aprons/
gowns and shoe bags. Hand washing before and after 
treatment with plenty of soap and water reinforced with 
the application of more than 60% alcohol. Staff should 
take vitamin C and gargle with salted water to clear the 
virus from the throat after dental procedures. All office 
waste should go into a red bag as an indicator of its high 
viral content in order to prevent the spread of viruses, 
bacteria, fungi, parasites, and prions.
It is recommended to record any possible case of CO-
VID-19 infection to serve as input and evidence of the 
advance of the virus to help alert as to possible muta-
tions of this virus. The data produced by the 40 000 den-
tists in Peru will be our contribution to the containment 
of this pandemic.
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